Olerup SSP[®] HLA-C*04:09N

Product number:	101.861-12 – including <i>Taq</i> polymerase 101.861-12u – without <i>Taq</i> polymerase
Lot number:	15N
Expiry date:	2014-July-01
Number of tests:	12
Number of wells per test:	2
Storage - pre-aliquoted primers:	dark at -20°C
- PCR Master Mix:	-20°C
 Adhesive PCR seals 	RT
- Product Insert	RT

This Product Description is only valid for Lot No. 15N.

CHANGES COMPARED TO THE PREVIOUS OLERUP SSP® HLA-C*04:09N LOT

The HLA-C*04:09N specificity and interpretation tables has been updated for the HLA-C alleles described since the previous Olerup SSP[®] HLA-C*04:09N lot (Lot No. 37M) was made.

The HLA-C*04:09N primer set is unchanged compared to the previous lot.

Lot No.: **15N**

Lot-specific information

PRODUCT DESCRIPTION

HLA-C*04:09N SSP subtyping

CONTENT

The primer set contains 5'- and 3'-primers for identifying the HLA-C*04:09N allele.

PLATE LAYOUT

Each test consists of 2 PCR reactions in an 8 well PCR plate. Wells 3 to 8 are empty.

	2	empty	empty	empty	empty	empty	empty
--	---	-------	-------	-------	-------	-------	-------

The 8 well cut PCR plate is marked with the Lot No. '15N' in silver/gray ink. Well No. 1 is marked with the Lot No. '15N'.

A faint row of numbers is seen between wells 1 and 2 or wells 7 and 8 of the PCR trays. These stem from the manufacture of the trays, and should be disregarded.

The PCR plates are heat-sealed with a PCR-compatible foil.

Please note: When removing each 8 well PCR plate, make sure that the remaining plates stay sealed. Use a scalpel or a similar instrument to carefully cut the foil between the plates.

INTERPRETATION

The interpretation of HLA-C*04:09N SSP subtypings will be influenced by the other C*04 alleles and the C*16:34 allele, when present on the other haplotype.

UNIQUELY IDENTIFIED ALLELES

The HLA-C*04:09N allele will give rise to a unique amplification pattern by the primers in the HLA-C*04:09N kit¹.

¹HLA-C alleles listed on the IMGT/HLA web page 2011-October-10, release 3.6.0, <u>www.ebi.ac.uk/imgt/hla</u>.

Lot No.: 15N

Lot-specific information

SPECIFICITY TABLE

HLA-C*04:09N SSP subtyping

Specificities and sizes of the PCR products of the 2 primer mixes used for HLA-C*04:09N SSP subtyping

Primer Mix	Size of spec. PCR product ¹	Size of control band ²	Amplified HLA-C alleles
1	220 bp	800 bp	*04:09N
2	255, 360 bp	1070 bp	*04:01:01:01-04:01:36, 04:03-04:20, 04:23-04:105N, *16:34

¹Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of HLA-C*04:09N SSP typings.

Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers.

PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings.

PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings.

Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherit feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated.

²The internal positive control primer pairs amplify segments of the human growth hormone gene. The two different control primer pairs give rise to either an internal positive control band of 1070 base pairs, for most wells, or a band of 800 base pairs, for some wells.

Well number 1 contains the primer pair giving rise to the shorter, 800 bp, internal positive control band in order to help in the correct orientation of the HLA-C*04:09N subtyping.

Lot-specific information

INTERPRETATION TABLE			
HLA-C*04:09N SSP ty	ping		
	Well		
	1	2	
Length of spec.	220	255	
PCR product		360	
Length of int.	800	1070	
pos. control ¹			
5'-primer(s) ²	1034	28	
	^{5'} -CTg ^{3'}	^{5'} -TCA ^{3'}	
3'-primer(s) ³	1092	112	
	^{5'} -TTA ^{3'}	^{5'} -CCA ^{3'}	
		118	
		^{5'} -gCT ^{3'}	
		218	
		^{5'} -gCT ^{3'}	
Well No.	1	2	
HLA-C allele			
*04:09N	1	2	
*04:01:01:01-04:01:36, 04:03-04:08,			
04:10-04:20, 04:23-04:105N,		2	
16:34			
HLA-C allele			
Well No.	1	2	

¹The internal positive control primer pairs amplify segments of the human growth hormone gene. The two different control primer pairs give rise to either an internal positive control band of 1070 base pairs, for most wells, or a band of 800 base pairs, for some wells.

Well number 1 contains the primer pair giving rise to the shorter, 800 bp, internal positive control band in order to help in the correct orientation of the HLA-C*04:09N subtyping. .

²The nucleotide position, in the 1st or 6th exon, matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

³The nucleotide position, in the 2nd or 7th exon, matching the specificity-determining 3'-end of the given in the anti-sense direction. Nucleotide numbering as on the primer is www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

HLA-C*04:09N

Product Insert

101. 861-12 – including *Taq* **polymerase**, IFU-01 Rev. No. 03 **101. 861-12u – without** *Taq* **polymerase**, IFU-02 Rev. No. 03

Lot No.: **15N**

Lot-specific information

"Instructions for Use" (IFU)

	HLA-C*04:0				W	ell
					1	2
				Lot No.:	201295201	201195202
		VC cell line		C*		
1	9001		*07:02		-	-
2		LK707	*07:01	*15:05	-	-
3		E4181324	*12:02		-	-
4		GU373	*03:04	*04:01	-	+
5		KAS011	*06:02		-	-
6	9353		*03:04	*07:02	-	-
7	9020		*05:01		-	-
8	9007		*04:01		-	+
9		YAR	*12:03		-	-
10		LKT3	*01:02		-	-
11		PITOUT	*16:01		-	-
12	9052		*06:02		-	-
13		JESTHOM	*01:02	*00.04	-	-
14		OLGA	*01:02	*03:04	-	-
15	9075		*03:04		-	-
16		SWEIG007	*02:02	*07.04	-	-
17		CTM3953540	*03:03	*07:01	-	-
18		32367	*01:02	*07:05	-	-
19		BM16	*07:01		-	-
20		SLE005	*03:04		-	-
21		AMALA	*03:03		-	-
22		KOSE	*12:03	*45.00	-	-
23	9124		*01:02	*15:02	-	-
24		JBUSH	*12:03		-	-
25		IBW9	*08:02		-	-
26		WT49	*07:01	*45.05	-	-
27		CH1007	*07:04	*15:05	-	-
28		BEL5GB	*05:01	*16:01	-	-
29	9050	MOU	*16:01		-	-
30 31		DUCAF	*17:01		-	-
31 32	9019		*17:01	*17:03	-	-
32 33		MT14B	*03:04	17.03	[-
33 34		DHIF	*12:03			-
34 35		SSTO	*05:01		1	-
35 36		KT17	*03:03	*04:01	-	- -
36 37		HHKB	*03:03	04.01		+
37 38	9065		*03:03		[_	-
30 39	9099		*02:02	*07:01	-	-
39 40		WHONP199	*01:02	*06:02		-
40		H0301	*08:02	00.02	-	-
41		TAB089	*01:02		<u>-</u>	-
42 43		T7526	*01:02	*08:01	-	-
43 44	9076		*12:03	00.01		
44 45				*17:01		-
-		SHJO	*06:02	17.01		-
46		SCHU	*07:02	*15.00		-
47	9045	TUBO	*07:04	*15:02	-	-

HLA-C*04:09NProduct Insert101. 861-12 – including Taq polymerase, IFU-01 Rev. No. 03101. 861-12u – without Taq polymerase, IFU-02 Rev. No. 03Lot No.: 15NLot-specific information

CERTIFICATE OF ANALYSIS

Olerup SSP[®] HLA-C*04:09N SSP

Product number:101.861-12 – including Taq polymerase
101.861-12u – without Taq polymeraseLot number:15NExpiry date:2014-July-01Number of tests:12Number of wells per test:2

Well specifications:

Well No.	Production No.
1	2011-952-01
2	2011-952-02

The specificity of each primer solution of the kit has been tested against 48 well characterized IHWC cell line DNAs.

Results: No false positive or false negative amplifications were obtained.

Date of approval: 2012-January-16

Approved by:

Production Quality Control

Lot-specific information

Declaration of Conformity

Product name: Product number: Lot number:	<i>Olerup</i> SSP [®] HLA-C*04:09N 101.861-12/12u 15N
Intended use:	HLA-C*04:09N histocompatibility testing
Manufacturer:	<i>Olerup</i> SSP AB Franzengatan 5 SE-112 51 Stockholm, Sweden <i>Phone:</i> +46-8-717 88 27 <i>Fax:</i> +46-8-717 88 18

We, Olerup SSP AB, hereby declare that this product, to which this Declaration of Conformity relates is in conformity with the following Standard(s) and other normative document(s) ISO 9001:2008 and ISO 13485:2003, following the provisions of the 98/79/EC Directive on in vitro diagnostic medical devices, Annex II List B, conformity assessed using Annex IV, as transposed into the national laws of the Member States of the European Union.

The Technical Documentation File is maintained at Olerup SSP AB, Franzengatan 5, SE-112 51 Stockholm, Sweden.

The Authorized Representative located within the Community is: Olerup SSP AB.

Stockholm, Sweden 2012-January-16

Ann-Cathrin Jareman Head of QA and Regulatory Affairs

ADDRESSES:

Manufacturer: Olerup SSP AB, Franzengatan 5, SE-112 51 Stockholm, Sweden. *Tel:* +46-8-717 88 27 *Fax:* +46-8-717 88 18 *E-mail:* <u>info-ssp@olerup.com</u> *Web page:* <u>http://www.olerup-ssp.com</u>

Distributed by: Olerup GmbH, Löwengasse 47 / 6, AT-1030 Vienna, Austria. *Tel:* +43-1-710 15 00 *Fax:* +43-1-710 15 00 10 *E-mail:* support-at@olerup.com *Web page:* http://www.olerup.com

Olerup Inc., 901 S. Bolmar St., Suite R, West Chester, PA 19382 *Tel:* 1-877-OLERUP1 *Fax:* 610-344-7989 *E-mail:* info.us@olerup.com *Web page:* http://www.olerup.com

For information on Olerup SSP distributors worldwide, contact Olerup GmbH.